Metformin Improves Overall Survival of Colorectal Cancer Patients with Diabetes: A Meta-Analysis
Open Access
- 8 February 2017
- journal article
- review article
- Published by Wiley in Journal of Diabetes Research
- Vol. 2017, 1-8
Abstract
Introduction. Diabetic population has a higher risk of colorectal cancer (CRC) incidence and mortality than nondiabetics. The role of metformin in CRC prognosis is still controversial. The meta-analysis aims to investigate whether metformin improves the survival of diabetic CRC patients.Methods. PubMed, EMBASE, and Cochrane Library were searched till July 1, 2016. Cohort studies were included. All articles were evaluated by Newcastle-Ottawa Scale. Hazard Ratios (HRs) with 95% confidence intervals (CIs) for each study were calculated and pooled HRs with corresponding 95% CIs were generated using the random-effects model. Heterogeneity and publication bias were assessed.Results. We included seven cohort studies with a medium heterogeneity (= 56.1% and) in our meta-analysis. An improved overall survival (OS) for metformin users over nonusers among colorectal cancers with diabetes was noted (HR 0.75; 95% CI 0.65 to 0.87). However, metformin reveals no benefits for cancer-specific survival (HR 0.79, 95%, CI 0.58 to 1.08).Conclusions. Metformin prolongs the OS of diabetic CRC patients, but it does not affect the CRC-specific survival. Metformin may be a good choice in treating CRC patients with diabetes mellitus in clinical settings.
Keywords
This publication has 32 references indexed in Scilit:
- Diabetes, metformin use, and colorectal cancer survival in postmenopausal womenCancer Epidemiology, 2013
- Disease-specific mortality among stage I–III colorectal cancer patients with diabetes: a large population-based analysisDiabetologia, 2012
- Survival advantage observed with the use of metformin in patients with type II diabetes and colorectal cancerBritish Journal of Cancer, 2012
- The effects of metformin on the survival of colorectal cancer patients with diabetes mellitusInternational Journal of Cancer, 2011
- The impact of type 2 diabetes mellitus on cancer‐specific survivalCancer, 2011
- Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analysesEuropean Journal of Epidemiology, 2010
- Diabetes mellitus negatively impacts survival of patients with colon cancer, particularly in stage II diseaseJournal of Cancer Research and Clinical Oncology, 2010
- The metabolic syndrome and risk of incident colorectal cancerCancer, 2006
- Role of AMP-activated protein kinase in mechanism of metformin actionJournal of Clinical Investigation, 2001
- Role of AMP-activated protein kinase in mechanism of metformin actionJournal of Clinical Investigation, 2001